Immunovant Inc IMVT Stock Analysis
- Nasdaq
- Stock
- Market open · no trades yet today
$29.07 down $0.83, 2.78% on Nov 5
Last price · Previous close $29.90
- Market cap
- At the last price
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$29.07down $0.83, 2.78%Thu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$29.90Nov 4
- Volume1.27MNov 4 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.36MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $21.43 to $45.42; now $29.07
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the last price. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
IMVT beat the S&P 500 in 3 of 6 periods.
| Period | IMVT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | IMVT: down 12.6% S&P 500: down 5.4% | IMVT trailed the S&P 500 by 7.2 percentage points Trailed |
| 3M | IMVT: down 26.0% S&P 500: down 4.5% | IMVT trailed the S&P 500 by 21.5 percentage points Trailed |
| YTD | IMVT: up 14.4% S&P 500: up 8.3% | IMVT beat the S&P 500 by 6.1 percentage points Beat |
| 1Y | IMVT: up 23.2% S&P 500: up 9.3% | IMVT beat the S&P 500 by 13.9 percentage points Beat |
| Long term | ||
| 3Y | IMVT: down 14.5% S&P 500: up 74.8% −5.1% vs +20.5% a year | IMVT trailed the S&P 500 by 89.3 percentage points Trailed |
| 5Y | IMVT: up 238.8% S&P 500: up 67.3% +27.6% vs +10.8% a year | IMVT beat the S&P 500 by 171.5 percentage points Beat |
$10,000 invested in IMVT 5 years ago (Nov 5, 2021) would be worth about $33,881 as of , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,730.
IMVT beat the S&P 500 in 3 of 6 periods.
| Period | IMVT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | IMVT: down 12.6% S&P 500: down 5.4% | IMVT trailed the S&P 500 by 7.2 percentage points Trailed |
| 3M | IMVT: down 26.0% S&P 500: down 4.8% | IMVT trailed the S&P 500 by 21.2 percentage points Trailed |
| YTD | IMVT: up 14.4% S&P 500: up 7.5% | IMVT beat the S&P 500 by 6.9 percentage points Beat |
| 1Y | IMVT: up 23.2% S&P 500: up 8.2% | IMVT beat the S&P 500 by 15.0 percentage points Beat |
| Long term | ||
| 3Y | IMVT: down 14.5% S&P 500: up 68.6% −5.1% vs +19.0% a year | IMVT trailed the S&P 500 by 83.1 percentage points Trailed |
| 5Y | IMVT: up 238.8% S&P 500: up 56.4% +27.6% vs +9.4% a year | IMVT beat the S&P 500 by 182.4 percentage points Beat |
$10,000 invested in IMVT 5 years ago (Nov 5, 2021) would be worth about $33,881 as of , not counting dividends. The same amount in the S&P 500 would be worth about $15,645.
All-time high
$52.71
Closing high on . Now 44.8% below that record.
Split-adjusted daily closes since Dec 19, 2019.
Stock splits
IMVT hasn’t split since its price history begins in 2019.
Valuation
Financials
About Immunovant Inc
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.
- Sector
- Industry
- Headquarters
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
IMVT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
IMVT stock FAQ
What is IMVT stock’s price today?
Immunovant (IMVT) traded at $29.07 as of , down $0.83 (2.78%) from the previous close of $29.90. Over the past 52 weeks it has traded between $21.43 and $45.42.
If you invested $1,000 in IMVT 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in IMVT on would be worth about $3,388 as of , a total return of +238.8%. The same $1,000 would be worth $1,232 if invested one year ago. Past performance doesn’t predict future returns.
Does IMVT pay a dividend?
Immunovant hasn’t paid a dividend in the last twelve months.
What is IMVT’s 52-week high and low?
Over the past 52 weeks IMVT has traded as low as $21.43 and as high as $45.42. At $29.07 as of , it is 36.0% below that high and 35.7% above the low.
What is IMVT’s all-time high?
IMVT’s highest closing price was $52.71 on , adjusted for stock splits. At $29.07 as of , it is 44.8% below that record.
Has IMVT stock ever split?
No. IMVT hasn’t split since its price history begins in 2019.
How has IMVT stock performed?
Including dividends and measured to the last price on , IMVT has returned +14.4% so far this year and +23.2% over the past year, and +238.8% over five years (+27.6% a year). Over the same periods the S&P 500, measured by SPY, returned +8.3%, +9.3% and +67.3%. Past performance doesn’t predict future returns.
What exchange does IMVT trade on?
Immunovant trades on the Nasdaq under the ticker symbol IMVT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.